Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.

Proceedings of the Fifth International Symposium, held in Abano Terme (Padova), italy, June 29-July 2, 1987

The decade of the 1990s will see an increasing emphasis on the modulation of chemotherapeutic drug selectivity and in the 'lock and key' approach to new targets to control malignant proliferation. The contents of this volume appropriately reflect these scientific undercurrents. An emerging powerful tool of molecular pharmacology is described by Holcenberg and Wu. Manipulation of genetic expression by modification of messenger RNA is now within our reach, and the basic concepts are suc- cinctly reviewed as a primer on future biochemical engineering of new anti- cancer molecules. Another concept that appears to be worthy of further study in both experimental and clinical chemotherapy concerns obs'ervations on the modulation of activity by the nucleoside transport inhibitor, dipyri- damole. How potentiation of several anticancer drugs occurs has practical, as well as theoretical, ramifications, discussed by Goel and HowelL Finally, O'Dwyer and La Creta present a fresh look at sensitization of chemotherapy by the hypoxic radiosensitizer, SR-2731.

Brain Neurosecretory Cytokines: Immune Response and Neuronal Survival summarizes the biological and chemical data of signal molecules of the brain neuroendocrine immune system, mainly proline-rich peptides, which play an important role in the regulation of immune response, neuronal survival, hematopoiesis, and adaptation. The author also describes the role of PRPs for the protection of neurons against neurodegenerative disturbances and diseases.
Brain Neurosecretory Cytokines: Immune Response and Neuronal Survival will be of great aid to the researchers and students in various areas of neurobiological profile (neurochemistry, neuroendocrinology, neurophysiology, and endocrinology).

This text provides a comprehensive overview of orthopaedic oncology - the field of orthopaedic surgery that specializes in the evaluation and treatment of bone and soft tissue tumors of the musculoskeletal system. The opening chapters cover musculoskeletal imaging interpretation and the principles of musculoskeletal biopsy. Assessment and treatment of the full range of tumors are then described in a series of well-illustrated chapters. Detailed consideration is given to benign tumors, osteosarcomas, Ewing sarcomas, chondrosarcomas, metastatic bone disease of the axial and appendicular skeleton, and soft tissue sarcomas. This book will be invaluable for both orthopaedic surgeons and medical oncologists, providing a framework for understanding the fundamentals of these tumors and a sound basis for their treatment.

about the involvement of signaling Transforming growth factor in tumor development and metastasis. plays a central role in the signaling network that controls morphogenesis, 2. THE BASICS OF growth and cell differentiation in SIGNALING multicellular organisms. The different members of this pleiotropic family of 2. 1. receptor signaling growth and differentiation factors seem to The family of growth factors regulate many processes in human disease consists of more than thirty members in and, in particular, tumor development. humans alone (15, 16). They cluster in Our understanding of how two major groups, the group composed of initiated signals are mediated has both the bone morphogenetic proteins increased dramatically in the last fifteen (BMP) and growth and differentiation years. Firstly, the prototype of factors (GDFs), and the group formed by this still constantly growing family, was the Activins, and Nodals. The two identified and cloned (1). Secondly, the groups differ in their use of receptors for family receptors were transmembrane receptors and the identified by expression cloning from subsequent activation of the mammalian tissue culture (2-7). Thirdly, transcriptional mediators (for recent genetic screens in Drosophila reviews see (13, 14, 17)).

In this issue of Hematology/Oncology Clinics, guest editors Drs. Matthew B. Yurgelun and Douglas A. Rubinson bring their considerable expertise to the topic of Pancreatic Cancer. Top experts in the field cover key topics such as pancreatic adenocarcinoma: trends in epidemiology, risk factors, and outcomes; decision making regarding perioperative therapy in individuals with localized pancreatic adenocarcinoma; the evolving role of radiotherapy in the management of individuals with pancreatic adenocarcinoma; and more. Contains 14 relevant, practice-oriented topics including diabetes, cachexia, sarcopenia, and metabolic factors in individuals with pancreatic adenocarcinoma; PARP inhibitors and other novel therapeutics in pancreatic adenocarcinoma; screening and surveillance for pancreatic adenocarcinoma in high-risk individuals; germline testing for individuals with pancreatic adenocarcinoma and novel genetic risk factors; and more. Provides in-depth clinical reviews on pancreatic cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Basophils and mast cells are similar but unique secretory cells with a well-documented role in immediate-hypersensitivity reactions. The presence of these cells in various cell mediated hypersensitivity reactions, in tissues of multiple diseases, and as a component of the host reaction to injury and repair in numerous circumstances is well known. Release of stored and newly generated mediators of inflammation from basophils and mast cells contributes to the cascade of pathogenetic events in circumstances under which these release reactions occur. Despite insights acquired through studies of these pathologic events, the role of basophils and mast cells and their secretory products in health is not known. In this book, I review much of the structural information regarding basophils and mast cells of multiple species. Ultrastructural studies of rat mast cells historically precede and quantitatively exceed similar studies of basophils and mast cells of other species. Therefore, I first review these background studies as an entity. Then I discuss the contents of two prominent organelles-granules and lipid bodies-in basophils and mast cells of several species. The ultrastructural morphology of basophils and mast cells in three species is presented in detail to establish appropriate guidelines for their recognition and to provide general rules for analysis which are appropriate for the identification of these cells in other species as well."

The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs."

A large proportion of cancers is preventable. External factors, discovered by epidemiological studies during the last 50 years, account for a majority of all cancer deaths. However, still rather little is known, about how environmental and genetic factors interact, how they may regulate gene activation etc. And it is a long way from the discovery of a basic regulatory mechanism to practical patient treatment. This volume describes the present state of the art in carcinogenesis, possibilities for cancer prevention, and gives genetic background in cancer development. Attention is given to the host-environment interaction, considering how this interaction may lead to cancer formation and how it can be utilised in cancer prevention. The molecular basis for cancer development and the molecular basis for prevention are described.

This volume provides broad insights to the most recent discoveries in telomere biology, with current applications in tumor diagnostics and future potentials in therapy. Special features of diverse organisms are presented, with ciliates, the "telomerase discoverer organisms"; yeasts, the "molecular genetisists' toy for eukaryotes"; including plants and insects as well. 28 chapters were written by a group of leading research scientists, working in the telomere/telomerase fields today. This book will be a core reference for any physician, scientist or "educated reader" with an interest in the exciting developments in this research field.

Nutrition, appetite, and involuntary weight loss are issues that affect a large number of cancer patients and cancer survivors. Aspects such as symptom management, behavioural modification, exercise and medication are all important aspects of cancer care, but nutritional issues at the end of life can be accompanied by contentious ethical factors as well as religious and cultural influences that need to be addressed by health professionals. This book enables physicians, nurses and also dieticians to better discuss these complex issues with patients and their families.
This comprehensive reference book provides both background information and practical, clinical advice for managing the cancer patient at all stages of their disease trajectory. It includes information that relates to patients who are continuing to receive disease-specific therapy, the cancer survivor, as well as patients with advanced or recurrent cancer receiving palliative care.
Basic principles such as epidemiology and physiology set the scene, leading into the cachexia/anorexia syndrome, treatment options, nutritional counselling, enteral and parenteral nutrition, complementary/alternative therapies, exercise, clinical outcomes measures in each of the clinical groups, and focus on special populations and their specific needs. Multidimensional, interdisciplinary clinical evaluation and treatment is emphasised, and ethical, religious, and cultural factors are also addressed.
Multidisciplinary in nature, this book draws on the experience of the editors' work across the fields of oncology, palliative care, surgery, primary care, nursing, dietetics and nutritional science. It will prove invaluable to all general practitioners, internists, medical oncologists and surgeons, nurses, palliative care specialists and related professionals involved in the care of the cancer patient.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdividions such as lung cancer, genitouri nary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general on cology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

This volume is the second in the 'Cancer Treatment and Research' series focussing on basic and clinical tumor immunology. It has a rather different focus or emphasis from that of the first volume, published two years ago. That work (Basic and Clinical Tumor Immunology, R.B. Herberman, ed., Martinus Nijhoff Publishers, 1983) devoted considerable attention to up dated summaries in various areas of classical tumor immunology: specific antitumor immunity, the immunologic competence of cancer patietns, char acterization of human tumor-associated antigens, the ability to propagate specifically immune T cells in culture in the presence of interleukin 2, and the use of such cells for adoptive immunotherapy of established tumors. of evidence concerning the immune However, it also reviewed the status surveillance hypothesis and pointed out the need to consider non-T cell mediated mechanisms of host resistance. In particular, one chapter sum marized information on the role of macrophages in host resistance against tumors. The present volume continues to emphasize one of the major themes of the first volume, innovative approaches to the therapy of cancer. It involves contributions from leading investigators on several primary types of therapeutic interventions related to monoclonal antibodies, the col laboration of monoclonal antibodies with macro phages to mediate antibody dependent cellular cytotoxicity, lymphokines, tumor vaccines, and natural killer cells. It also has an up-to-date summary of the immunologic aspects of the exciting and promising work being performed on human T cell leukemia virus in the laboratory of Dr. Robert Gallo."

This work describes the importance of tumor microenvironment in favouring tumor progression and angiogenesis. Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment and requires the functional activities of a number of molecules, including angiogenic factors, extracellular matrix proteins, adhesion molecules and proteolytic enzymes. In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors for endothelial cells, that stimulate the growth of the blood vessels of the host or the down-regulation of natural angiogenesis inhibitors. In particular, the inflammatory infiltrate may contribute to tumor angiogenesis, and there are many reports of associations between tumor inflammatory infiltrate, vascularity and prognosis. New therapeutic approaches have been developed with the aim to control tumor angiogenesis through targeting of different components of tumor microenvironment.

The last volume dealing with lung cancer in this series in Cancer Treatment and Research was published in 1986 and entitled Lung Cancer: Basic and Clinical Aspects. The present book continues the outline of the previous volume by presenting up-to-date information on lung cancer in critical reviews of new important basic and clinical concepts of lung cancer. The present volume has broadened the scope by also including chapters dealing with issues such as epidemiology, prophylaxis, and histopathology of lung cancer. The content of the book thus reflects the increasing awareness of a global disease that is more and more in focus, not only scientifically but also politically. The latter fact results increasingly in changes in health legisla tion, with prevention measures influencing everyday life. The great interest in the disease is natural, considering that more than one patient dies from lung cancer every minute globally. The first chapter is from the Cancer Unit, WHO, Geneva, and describes in detail the epidemiologic features of lung cancer, which is the second most frequent cancer in the world with 660,500 new cases annually; it will soon surpass stomach cancer as the leader. Thirty-one percent of the cases occur in developing countries, where the increase is especially dramatic."

Where do you begin to look for a recent, authoritative article on the diag nosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals fre quently publish good in-depth reviews of cancer topics, and published sym posium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by di viding the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

The current volume represents the fourth over a period of five years in our series on Advances in the Cellular and Molecular Biology of Breast Cancer. The first three volumes were entitled Breast Cancer: Cellular and Molecular Biology, Regulatory Mechanisms in Breast Cancer, and Genes, Oncogenes, and Hormones, respectively. Throughout this series, we have tried to take a broad look at cutting-edge topics in basic science research into breast cancer. This attempt has resulted in a wide range of subject material, including rodent and human model systems, oncogenes, suppressor genes, growth factors, hormones, tumor-host interactions, and determinants of metastases. Since our last volume, research in breast cancer has continued to proceed at an explosive rate. We hope the current volume will provide the reader with some of the excitement felt by the editors and authors as we begin to understand this all-too-common disease. The first section of this book is devoted to the basic processes of proli feration, differentiation, and malignant progression of breast cancer. T.l. Anderson and W.R. Miller lead off with a detailed description of controls on proliferation in the normal human breast and in breast cancer. This chapter strongly emphasizes pathological aspects. The second chapter, by M.R. Stampfer and P. Yaswen, presents a corresponding viewpoint through a presentation of experiments with human mammary epithelial cells in culture. The second section of the book emphasizes the genetic basis for breast cancer onset and malignant progression. Chapter 3, by M.-C. King and S."

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, and easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc.; and second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current di agnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Now divided into four parts, the second edition of Cancer Pain delivers broad coverage of the issues that arise in the management of malignancy-related pain, from basic science, through end of life care and associated ethical issues, to therapies, both medical and complementary. Part One reviews basis considerations in cancer pain management, including epidemiology, pharmacology, history-taking and patient evaluation and teamworking. Part Two brings together the drug therapies for cancer pain, their underlying basis, and potential side-effects. Part Three covers the non-drug therapies, including nerve blocks, stimulation-induced analgesia, radiotherapy, complementary therapies and psychological interventions. The control of symptoms other than pain, so critical to cancer patients, is also considered here. Part Four describes special situations. Cancer pain management in children and older patients, and in the community setting, and pain in the dying patient and the cancer survivor are all covered here.

Cancer is one of the leading killers in the world and the incidence is increasing, but most cancer patients and cancer survivors suffer much from the disease and its conventional treatments' side effects. In the past, clinical data showed that some complementary and alternative medicine (CAM) possessed anticancer abilities, but some clinicians and scientists have queried about the scientific validity of CAM due to the lack of scientific evidence. There is great demand in the knowledge gap to explore the scientific and evidence-based knowledge of CAM in the anticancer field. With this aim, a book series is needed to structurally deliver the knowledge to readers. Recently there have been encouraging results from both laboratory experiments and clinical trials demonstrating the anticancer effects of herbal medicine. There is considerable interest among oncologists and cancer researchers to find anticancer agents in herbal medicine. This volume is a specialised book presenting the up-to-date scientific evidence for anticancer herbal medicine. This unique book provides an overview of the anticancer herbal medicines and remedies, as well as a detailed evidence-based evaluation of 18 common anticancer herbal medicines covering their biological and pharmacological properties, efficacies, herb-drug interactions, adverse effects, pre-clinical studies, and clinical applications. Gathering international opinion leaders' views, this volume will contribute great to the cancer, academic, and clinical community by providing evidence-based information on the anticancer efficacy of herbal medicine. Readership Oncologists, cancer researchers, pharmacologists, pharmaceutical specialists, Chinese medicine practitioners, medical educators, postgraduates and advanced undergraduates in biomedical disciplines, cancer caregivers, cancer patients.

There is extremely compelling evidence to suggest that if people are physically active before, during and after cancer treatment, their outcomes are likely to be better. Their risk of recurrence (and death) is lower and their ability to deal with the myriad side effects is improved significantly. Increasingly people with cancer understand this but they are often unsure of what exercise would be best, what is safest, what would be most effective and what to avoid. This book offers very practical, targeted information to enable people to exercise in whatever way they feel ready for. It provides guidance on effective and appropriate exercise for anybody who has received a diagnosis of cancer, including those receiving active treatment and those living with incurable cancer of all types, with the emphasis on the proven benefits of exercise and activity.